AI-HEART Lab Clinical Tools
2022 AHA/ACC/HFSA Heart Failure Guideline Calculator
Guideline-informed decision-support across 13 integrated modules. Classify heart failure stage, optimize GDMT, evaluate device therapy, and manage comorbidities.
HIPAA-Compliant
- Calculator runs 100% in your browser — no patient data is transmitted
- AI features process data under a signed HIPAA BAA with zero data retention
How It Works
Classify HF Stage
Enter patient data to classify heart failure stage (A through D) and phenotype (HFrEF, HFmrEF, HFpEF)
Review GDMT
Get guideline-directed medical therapy recommendations with target doses and titration guidance
Assess Devices
Evaluate indications for ICD, CRT, and mechanical circulatory support based on patient profile
Manage Comorbidities
Address AF, CAD, CKD, diabetes, iron deficiency, and other conditions that impact HF outcomes
Heart Failure Pathophysiology
Neurohormonal activation (RAAS, SNS), cardiac remodeling, volume overload and congestion, four-pillar GDMT mechanisms of action, and device therapy rationale.
Explore mechanisms →Landmark Trials That Shaped the 2022 Guideline
- PARADIGM-HF: ARNi reduced CV death and HF hospitalization by 20% vs enalapril in HFrEF
- DAPA-HF: Dapagliflozin reduced worsening HF or CV death by 26% in HFrEF regardless of diabetes
- EMPEROR-Preserved: Empagliflozin reduced HF hospitalization in HFpEF — first positive RCT in this population
- DELIVER: Dapagliflozin reduced worsening HF or CV death by 18% in HFpEF and HFmrEF
- ATTR-ACT: Tafamidis reduced mortality and CV hospitalizations in transthyretin cardiac amyloidosis
Stay Current on Heart Failure Evidence
— landmark trials and significant new findings, with AI-contextualized summaries
0 of 13 modules completed
IMPORTANT: This software is clinical decision support (CDS) intended for use by licensed healthcare professionals under Section 520(o)(1)(E) of the Federal Food, Drug, and Cosmetic Act. It is not intended as a medical device. All recommendations are derived from the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure and must be independently verified by the treating clinician before any clinical action. AI-generated content (including extracted data and clinical notes) is produced by large language models and may contain errors, omissions, or hallucinations — clinician review is mandatory. Patient data entered into the calculator is processed entirely in the browser; AI features process data server-side under a signed HIPAA Business Associate Agreement with no data retention. AI-HEART Lab, its affiliates, and contributors assume no liability for clinical decisions made using this tool. By using this tool, you acknowledge these limitations and accept full responsibility for clinical decisions.
Calculator computation is 100% client-side. Opt-in AI features process data server-side under a signed HIPAA BAA with no data retention.
About This Tool
This calculator implements the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Every clinical threshold — HF stage classification, LVEF cutoffs, GDMT drug selection, device therapy indications, and BP/HR targets — is mapped directly to the corresponding guideline figure, table, or recommendation with Class of Recommendation (COR) and Level of Evidence (LOE) cited.
The tool includes 13 core modules covering HF classification, diagnostic evaluation, risk stratification, prevention (Stage A), pre-HF (Stage B), HFrEF GDMT, device therapy, HFmrEF management, HFpEF management, cardiac amyloidosis, advanced HF, comorbidity management, and special populations. Patient data flows between modules — an LVEF classification automatically informs treatment recommendations across the tool.
Calculator computation occurs entirely in your browser. Opt-in AI features (data extraction, note generation, email delivery) process clinical data server-side under a signed HIPAA Business Associate Agreement — data is held in memory only and never persisted or logged.
Key Updates in the 2022 HF Guideline
The 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure represents the first comprehensive update since 2013/2017. Published in April 2022, it introduces SGLT2 inhibitors as foundational GDMT, formally recognizes HFmrEF, and provides new guidance on cardiac amyloidosis.
SGLT2 Inhibitors as Foundational Therapy
For the first time, SGLT2 inhibitors (dapagliflozin and empagliflozin) received a Class 1 recommendation for HFrEF based on DAPA-HF and EMPEROR-Reduced trials. They are recommended regardless of diabetes status. For HFpEF, SGLT2 inhibitors received Class 2a recommendation based on EMPEROR-Preserved and DELIVER data, making them the first drug class with positive RCT evidence in this challenging population.
Revised HF Classification
The guideline formally introduces “heart failure with mildly reduced ejection fraction” (HFmrEF, LVEF 41–49%) as a distinct category, replacing the previous “HFpEF borderline” terminology. Stage B is now termed “pre-HF” to better reflect asymptomatic structural or biomarker abnormalities preceding clinical HF. The term “HFpEF improved” is introduced for patients whose LVEF recovers above 40%.
Cardiac Amyloidosis Recognition
The 2022 guideline provides dedicated recommendations for cardiac amyloidosis for the first time. Tafamidis receives a Class 1 recommendation for ATTR cardiomyopathy (NYHA I–III) based on ATTR-ACT trial data. Screening algorithms including technetium pyrophosphate scintigraphy and genetic testing are formally incorporated into the diagnostic evaluation pathway.
ARNi as Preferred Over ACEi/ARB
Sacubitril/valsartan (ARNi) is now the preferred first-line neurohormonal agent over ACEi or ARB in HFrEF (COR 1, LOE A), based on PARADIGM-HF. De novo initiation is supported without prior ACEi/ARB exposure. A 36-hour washout period is required when switching from ACEi to ARNi to avoid angioedema risk.
Why Use This Calculator
13 Integrated Clinical Modules
Each module maps directly to the guideline's clinical decision algorithms: HF classification, diagnostic evaluation and biomarkers, risk stratification, Stage A prevention, Stage B pre-HF management, HFrEF four-pillar GDMT, device therapy (ICD, CRT, LVAD), HFmrEF management, HFpEF management, cardiac amyloidosis, advanced HF, comorbidity management, and special populations. Patient data flows between modules — an LVEF entry in Module 1 automatically informs GDMT and device therapy recommendations.
Privacy and Data Handling
Calculator computation runs entirely in your browser with no server transmission. There are no user accounts, no cookies storing clinical data, and no analytics tracking patient inputs. Opt-in AI features (data extraction, note generation, email delivery) process clinical data server-side under a signed HIPAA Business Associate Agreement — data is held in memory only and never persisted or logged.
Built by a Practicing Cardiologist
This calculator was developed by Dr. Rahul Chaudhary, a practicing cardiologist (FACP, FACC) and physician-scientist with 150+ peer-reviewed publications, 18 international guideline citations, and training at Johns Hopkins University and UPMC, former faculty at Mayo Clinic Rochester. Every clinical threshold is mapped to a specific guideline figure or table with source documentation.
Frequently Asked Questions
What are the heart failure stages?
Stage A: at risk for HF (hypertension, diabetes, obesity, CAD) without structural disease. Stage B: pre-HF with structural heart disease or elevated biomarkers without HF symptoms. Stage C: symptomatic HF classified by LVEF as HFrEF (≤40%), HFmrEF (41–49%), or HFpEF (≥50%). Stage D: advanced HF requiring specialized interventions (LVAD, transplant, palliative care).
What is the four-pillar GDMT for HFrEF?
The 2022 guideline recommends four foundational drug classes for HFrEF: (1) ARNi (sacubitril/valsartan, preferred) or ACEi/ARB, (2) evidence-based beta-blocker (carvedilol, metoprolol succinate, or bisoprolol), (3) mineralocorticoid receptor antagonist (spironolactone or eplerenone), and (4) SGLT2 inhibitor (dapagliflozin or empagliflozin). All four should be initiated and titrated to guideline-recommended target doses.
When are SGLT2 inhibitors indicated in heart failure?
SGLT2 inhibitors are Class 1 recommended for HFrEF (LVEF ≤40%) and Class 2a for HFpEF/HFmrEF (LVEF >40%), regardless of diabetes status. Evidence from DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved, and DELIVER demonstrates reductions in HF hospitalization and cardiovascular death across the LVEF spectrum.
How is cardiac amyloidosis managed?
Tafamidis is recommended (COR 1, LOE B-R) for ATTR cardiomyopathy (both wild-type and hereditary) in NYHA class I–III based on ATTR-ACT trial data. Screening with technetium pyrophosphate scintigraphy and serum/urine immunofixation is recommended when amyloidosis is suspected. Traditional HF medications (beta-blockers, ACEi/ARB) are often poorly tolerated in cardiac amyloidosis.
Does this calculator store or transmit patient data?
Calculator computation occurs entirely in your browser with no server transmission. Opt-in AI features (data extraction, AI-generated notes, email delivery) process clinical data server-side under a signed HIPAA Business Associate Agreement — data is held in memory only during the request and is never persisted, cached, or logged.
Reference
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063
Developed by AI-HEART Lab
Built by Dr. Rahul Chaudhary, a physician-scientist with 150+ publications and 18 international guideline citations, trained at Johns Hopkins University and UPMC, former faculty at Mayo Clinic Rochester.